|
View these ASCP videos to learn more about HER2-low and HER2-ultralow breast cancer: Defining HER2-Low and HER2-Ultralow Breast Cancer The Concept of HER2 IHC 0+ in Breast Cancer Reporting Low and Ultralow Levels of HER2 Expression in Breast Cancer Targeted Therapy for HER2-low and HER2-ultralow Advanced Breast Cancer Be sure to take a look at this new ASCP online certificate program on cancer biomarker testing navigation!
www.ascp.org/education/learning-format/certificate-programs/btn Real-world findings from a multi-institutional quality study using CFIR to explore gaps, challenges, and opportunities around implementing precision medicine in community cancer settings.
doi.org/10.1200/JCO.2025.43.16_suppl.e23157 Don't miss these ASCP online CME activities on NSCLC biomarker testing:
Current NSCLC Biomarker Testing Guidelines store.ascp.org/productlisting/productdetail?productId=175665242 Optimizing Sample Sizes for NSCLC Biomarker Testing store.ascp.org/productlisting/productdetail?productId=175665739 Equity of Biomarker Testing in NSCLC store.ascp.org/productlisting/productdetail?productId=175666685 Optimizing Testing in The Laboratory with A Special Focus on Antibody Validation store.ascp.org/productlisting/productdetail?productId=175682683 Dr. Joseph Kim, President of Q Synthesis LLC, is honored to be added to the OncoLens Advisory Board!
OncoLens is an oncology-focused digital health platform that enhances cancer care through proprietary AI-driven analytics and multidisciplinary collaboration tools. By leveraging structured and unstructured data, OncoLens improves patient outcomes and revenue opportunities by preventing patient leakage and proactively identifying patients for clinical trials, biomarker testing or other key services. The platform's analytics tools enable both centers and industry to derive insights into patient cohorts, identify new opportunities and improve quality. The OncoLens Research Network collaborates with industry partners to bring curated research and real world evidence initiatives to cancer centers. www.prweb.com/releases/oncolens-expands-board-with-addition-of-dr-prasanth-reddy-and-welcomes-advisory-members-dr-joseph-kim-and-dr-walter-curran-302458293.html  Pineault L, Valencia K, Buhay J, Brown A, Ziemnik S, Kelly M, Morgante J, Datta Mitra A, Yanamura L, Gilliland M, Ferea A, Kim J. ASCP explores the cancer biomarker testing navigator as a novel role to improve laboratory operations and workflows: A special report from the ASCP Biomarker Testing Navigator Project Team. Am J Clin Pathol. 2025 May 7:aqaf028. doi: 10.1093/ajcp/aqaf028. Epub ahead of print. PMID: 40329479. doi.org/10.1093/ajcp/aqaf028 ASCP has recently developed several CME activities on the topic of HER2-low and HER2-ultralow breast cancer:
Best Practices in HER2-low and HER2-ultralow Advanced Breast Cancer: IHC Testing and Interpretation Link: https://store.ascp.org/productlisting/productdetail?productId=176966209 Best Practices in HER2-low and HER2-ultralow Advanced Breast Cancer: Emerging Science and Current Treatment Link: https://store.ascp.org/productlisting/productdetail?productId=176989985 Best Practices in HER2-low and HER2-ultralow Advanced Breast Cancer: Reproducibility of Testing Link: https://store.ascp.org/productlisting/productdetail?productId=176990098 Congratulations to the collaborative efforts of ASCP and Q Synthesis for winning the 2025 Award for Outstanding Outcomes in CE Assessment! The project: “Building Knowledge and Skills in Biomarker Testing and Assessment of Pathological Response to Improve Care for Patients with Non-Small Cell Lung Cancer and Melanoma” was supported by an educational grant from BMS.  The Joint Commission and the National Association for Healthcare Quality Form Strategic Alliance to Advance Global Patient Safety and Healthcare Quality
(CHICAGO and OAKBROOK TERRACE, Illinois, November 19, 2024) – The Joint Commission and the National Association for Healthcare Quality (NAHQ) announce a strategic alliance to advance global healthcare Quality and safety for all. The alliance stems from a shared vision for safe, high-quality and equitable healthcare between NAHQ, the industry leader in defining Quality competencies and developing and certifying the healthcare Quality workforce, and The Joint Commission, the world’s premier and most recognized brand in standards-setting and accrediting body in healthcare. Read more about this here: www.jointcommission.org/resources/news-and-multimedia/news/2024/11/the-joint-commission-and-nahq-form-strategic-alliance/ Obesity Change Makers: National Quality Improvement Initiative to Improve Evidence-Based Care
Presented at ObesityWeek 2024 Learn more about this project here: clinicaloptions.com/content/qi-obesity QI Toolkit: clinicaloptions.com/activities/endocrinology-diabetes-metabolism/obesity-qi-tool-kit/17391-24775/info |
